TRIQ Searching for TRans-eQTL affecting the risk to develop Inflammatory Bowel Disease
- Coordinator
- Universite De Liege, Belgium
- Runs
- 1 May 2024 to 30 April 2026
- Status
- Running
- EU funding
- €192k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101155061
What the project is doing
In the project's own words, from its summary on CORDIS.
Inflammatory Bowel Disease, including Crohn’s disease and ulcerative colitis, now afflict close to 1/250 individuals in industrialized societies. There is a pressing need for effective preventive means as well as curative drugs. Cis-eQTL analyses are uncovering a growing list of genes that are perturbed by IBD risk variants detected by GWAS, constituting a list of prime drug targets for the pharmaceutical industry. Cis-eQTL effects trigger downstream effects – both within the same (intracellular) and other cell types (intercellular) – that culminate in disease declaration.
Some of these downstream effects are accompanied by changes in transcript levels referred to as trans-eQTL effects. The aim of the TRIQ project is to take advantage of the CEDAR-II dataset – transcriptome data for up to 400 individuals in > 75 IBD-relevant cell types – to identify trans-eQTL effects that mediate IBD predisposition. The genes that are perturbed by these trans-effect will include druggable targets that constitute prime targets for the development of new IBD therapies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite De Liege | Liege | Belgium | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI